Member access

4-Traders Homepage  >  Shares  >  London Stock Exchange  >  Hikma Pharmaceuticals Plc    HIK   GB00B0LCW083

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Hikma Pharmaceuticals : Ben Venue Laboratories, Inc. Announces Divestiture Of Assets Of Bedford Laboratories, Inc. To Hikma Pharmaceuticals PLC

06/04/2014 | 05:55pm US/Eastern

By a News Reporter-Staff News Editor at Pharma Business Week -- Ben Venue Laboratories. Inc. ("Ben Venue"), a member of the Boehringer Ingelheim Group of Companies, announced that the company has signed an asset purchase agreement for the sale of the assets of Bedford Laboratories, Ben Venue's U.S. injectable generics business to Hikma Pharmaceuticals PLC ("Hikma"). Bedford Laboratories is a leading provider of generic sterile injectable medicines in the U.S., with a focus on acute-care hospitals, group purchasing organizations and oncology treatment centers. Under the terms of the agreement, Hikma will be acquiring Bedford Laboratories' assets, including a large product portfolio, intellectual property rights, contracts for products marketed under license, raw material inventories, a strong research and development (R&D) and business development pipeline, and a number of employees across key business functions, such as R&D, sales and marketing, business development and regulatory affairs (see also Ben Venue Laboratories, Inc.).

"We believe that this is a positive development, allowing Hikma to leverage its existing infrastructure and manufacturing capabilities to re-introduce important products to the U.S. market, bringing significant benefit to patients," said Paul R. Fonteyne, U.S. Country Managing Director, President and CEO of Boehringer Ingelheim USA Corporation and Chairman, Ben Venue Board of Directors. "For more than 20 years, Bedford Laboratories and its product portfolio have been of great value to patients, customers and the marketplace. As part of Hikma, the Bedford team will remain focused on strengthening its relationships with customers and continuing to serve the needs of patients."

"I am very excited to be acquiring an impressive portfolio of Bedford's products and deep pipeline, which will significantly increase the scale and scope of our rapidly growing U.S. Injectables business. Our focus on bringing back critical products to the market that are currently in short supply will bring significant benefit to patients," said Said Darwazah, Chief Executive Officer of Hikma. "I am confident that we have the technical capabilities and manufacturing expertise to successfully re-launch Bedford's products in the near term. Our experience in integrating previous acquisitions will help to ensure a smooth integration."

In addition, Hikma has entered into an exclusivity arrangement with the Boehringer Ingelheim Group to potentially acquire substantially all of the assets of the Ben Venue manufacturing facility, subject to due diligence and customary approvals in the U.S. and the U.K.

Bank of America Merrill Lynch acted as the financial advisor, and Covington & Burling LLP acted as counsel, to Ben Venue.

Keywords for this news article include: Ben Venue Laboratories Inc.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

(c) 2014 Pharma Business Week via NewsRx.com

React to this article
Latest news on HIKMA PHARMACEUTICALS PLC
12:48pDJLONDON MARKETS : Tullow Oil, Mining Shares Put Pressure On FTSE 100
12:46pDJLONDON MARKETS : Tullow Oil, Mining Shares Put Pressure On FTSE 100
12:36pDJLONDON MARKETS : Tullow Oil, Mining Shares Put Pressure On FTSE 100
12:32pDJLONDON MARKETS : Tullow Oil, Mining Shares Put Pressure On FTSE 100
12:31pDJLONDON MARKETS : Tullow Oil, Mining Shares Put Pressure On FTSE 100
08:05aDJHikma Pharmaceutical Set to Replace Tullow Oil on FTSE100
02/26 HIKMA PHARMACEUTICALS : BRIEF: Hikma signs exclusive licence agreement with Azan..
02/26 HIKMA PHARMACEUTICALS : signs exclusive license agreement with Azanta for Nimora..
02/25 HIKMA PHARMACEUTICALS : First Jordanian Site to Receive ISO 50001 Certification
02/03 HIKMA PHARMACEUTICALS : *gs raises hikma pharmaceuticals price target to 2410 pe..
Advertisement
Chart
Duration : Period :
Hikma Pharmaceuticals Plc Technical Analysis Chart | HIK | GB00B0LCW083 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF